Quality of warfarin control in atrial fibrillation patients in South East Queensland, Australia

@article{Bernaitis2016QualityOW,
  title={Quality of warfarin control in atrial fibrillation patients in South East Queensland, Australia},
  author={Nijole Bernaitis and Tony Badrick and A K Davey and Shailendra Anoopkumar-Dukie},
  journal={Internal Medicine Journal},
  year={2016},
  volume={46}
}
Warfarin is widely prescribed to decrease the risk of stroke in atrial fibrillation (AF) patients. Due to patient variability in response, regular monitoring is required, and time in therapeutic range (TTR) used to indicate quality of warfarin control with a TTR>60% is recommended. Recently, an Australian Government review of anticoagulants identified the need to establish current warfarin control and determine the potential place of the newer oral anticoagulants. 
View on Wiley
csanz.edu.au
17 Citations
Highly Influential Citations
1
Background Citations
5
Methods Citations
1
Results Citations
1

17 Citations

Citation Type

Citation Type

Dedicated warfarin care programme results in superior warfarin control in Queensland, Australia
TLDR
The aim of this study was to compare the level of warfarin control in patients managed by their general practitioner and a Warfarin care programme (WCP) by Sullivan Nicolaides Pathology.
A High HASBLED Score Identifies Poor Warfarin Control in Patients Treated for Non‐Valvular Atrial Fibrillation in Australia and Singapore
TLDR
A HASBLED score ≥3 in patients treated with warfarin can differentiate significantly lower TTRs in Australian and Singapore patients with AF, and identifies patients with poor control in both Australia and Singapore.
Factors influencing warfarin control in Australia and Singapore.
Factors Affecting Quality of Anticoagulation Achieved with Warfarin as Thromboprophylaxis for Stroke Prevention in Non-valvular Atrial Fibrillation
TLDR
Individually, alcoholism, diabetes mellitus, hypertension and chronic kidney disease were found to be predictors of poor anticoagulation control i,e.
Warfarin control in patients transitioning to warfarin after non-vitamin K oral anticoagulant (NOAC) therapy
TLDR
There was no significant difference in warFarin control before changing to NOACs and after reverting to warfarin (mean TTR 75%) but significantly more frequent testing and lower doses were required to achieve this control.
The SAMe-TT2R2 Score Predicts Warfarin Control in an Australian Population with Atrial Fibrillation
TLDR
In Australia, the SAMe-TT2R2 score could assist clinicians in identifying Australian patients who may obtain reduced warfarin control and benefit from additional interventions such as a dedicated WCP.
The Use of Fish Oil with Warfarin Does Not Significantly Affect either the International Normalised Ratio or Incidence of Adverse Events in Patients with Atrial Fibrillation and Deep Vein Thrombosis: A Retrospective Study
TLDR
Omega-3 supplementation with fish and krill oil does not significantly affect long-term warfarin control and bleeding and thromboembolic events when consumed concurrently in patients managed at an anticoagulation clinic.
Physician–Pharmacist Collaborative Clinic Model to Improve Anticoagulation Quality in Atrial Fibrillation Patients Receiving Warfarin: An Analysis of Time in Therapeutic Range and a Nomogram Development
TLDR
The PPCC model contributed to improved anticoagulation quality in AF patients receiving warfarin and could aid physicians and pharmacists in the selection of patients who will likely benefit from sustained and active intervention.
The SAMe–TT2R2 score as an indicator of warfarin control for patients with deep vein thrombosis in Queensland, Australia
TLDR
The SAMe–TT2R2 score may assist in identifying patients with VTE likely to achieve good control (TTR ≥ 65%), but further investigation is required to determine the most suitable model for predicting warfarin control in this population.
Time to Stable Therapeutic Range on Initiation of Warfarin as an Indicator of Control.
...
1
2
...

References

SHOWING 1-10 OF 34 REFERENCES
New anticoagulants in atrial fibrillation: an update for clinicians
TLDR
New classes of anticoagulants have recently emerged with the potential for improved efficacy, safety and convenience, and direct thrombin inhibitor and Factor Xa inhibitor classes are showing promise for both patients and clinicians.
Quality of Anticoagulation Control and Costs of Monitoring Warfarin Therapy among Patients with Atrial Fibrillation in Clinic Settings: A Multi-Site Managed-Care Study
TLDR
In 3 geographically diverse health plans, anticoagulation clinics provided a generally higher quality of control than previously reported in other observational studies, and the costs of obtaining this level of control are highlighted.
Gaps in translation from trials to practice: non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation.
TLDR
The objectives of this review are to identify gaps in current knowledge regarding use of these single target anticoagulant drugs, and outline the potential implications of these gaps for clinical practice.
Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range
TLDR
For centers and countries, a target threshold TTR exists (estimated between 58% and 65%) below which there appears to be little benefit of OAC over antiplatelet therapy, and a wide variation exists in international normalized ratio control, as measured by TTR, between clinical centers and between countries.
An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation.
TLDR
Among patients with atrial fibrillation, anticoagulant prophylaxis is effective at INRs of 2.0 or greater, and tight control of anticoAGulant therapy to maintain the INR between2.0 and 3.0 is a better strategy than targeting lower, less effective levels of antICOagulation.
The quality of international normalised ratio control in southern Tasmania
TLDR
Australian “real-world” INR control was better than expected and, at the observed level of InR control, the benefits of novel anticoagulants compared with warfarin may be lost for most patients.
Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V.
TLDR
In patients with atrial fibrillation taking warfarin, the risks of death, MI, major bleeding, and stroke or SEE are related to INR control, and good InR control is important to improve patient outcomes.
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA.
TLDR
Compared with prospective randomized trials of warfarin treatment, TTR in the AuriculA population was higher and Complications were low, probably due to the organization of anticoagulation treatment in Sweden.
Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical Trial
TLDR
Regional differences in mean i‐TTR are heavily influenced by subtherapeutic INR values and are associated with reduced frequency of INR testing, while previous warfarin use and geographic region where patients were managed are dominant determinants of variation in i-TTR.
...
1
2
3
4
...